片頭痛治療薬市場規模、シェア、成長分析、治療クラス別、投与経路別、地域別 - 産業予測、2024年～2031年

片頭痛治療薬の世界市場規模は、2022年に38億9,000万米ドルと評価され、2023年の45億米ドルから2031年には172億5,000万米ドルに成長し、予測期間（2024-2031年）のCAGRは18.0%で成長する見通しです。

片頭痛治療薬市場は、主に片頭痛症状の緩和や予防を目的とした薬剤に焦点を当てており、急性治療薬と予防薬に分類されます。急性治療薬は片頭痛発作の即時緩和を目的とし、予防薬は発作の頻度と重症度の軽減を目的とします。市場成長の主な促進要因としては、効果的な予防法をめぐる意識の高まり、診断能力の進歩、革新的医薬品のイントロダクションなどが挙げられます。しかし、新しい治療法の高額な費用や、医療従事者と患者の双方が躊躇する潜在的な副作用などの課題も残っています。このような障害にもかかわらず、片頭痛治療薬市場は、医薬品開発の進歩、個別化医療へのシフト、新興国市場における有望な機会などに後押しされ、今後数年間で大きく拡大する見通しです。利害関係者がアンメットメディカルニーズに対応し、片頭痛管理における患者の転帰を改善しようとしているためです。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の想定と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要のトレンド分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 推進力と機会
  • 抑制要因と課題
• ポーター分析と影響
  • 競争企業間の敵対関係
  • 代替品の脅威
  • 買い手の交渉力
  • 新規参入業者の脅威
  • 供給企業の交渉力

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 技術の進歩
• 規制情勢
• 特許分析
• バリューチェーン分析
• ケーススタディ分析
• PESTEL分析
• マクロ経済指標
• 貿易分析
• 市場の魅力指数
• サプライチェーン分析
• 価格分析

片頭痛治療薬市場：治療別

• 急性
• 予防

片頭痛治療薬市場：治療クラス別

• CGRPモノクローナル抗体
• CGRP小分子拮抗薬
• アセチルコリン阻害剤/神経毒
• トリプタン
• ジタン
• 麦角アルカロイド
• NSAIDs
• その他

片頭痛治療薬市場：投与経路別

• 経口
• 注射
• その他

片頭痛治療薬市場：年齢層別

• 小児用
• 成人用
• 老人用

片頭痛治療薬市場：入手可能別

• 処方薬
• 市販薬（OTC）

片頭痛治療薬市場規模：地域別

• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • スペイン
  • フランス
  • イタリア
  • その他欧州地域
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東およびアフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2023年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2023年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2021-2023）

主要企業プロファイル

• Pfizer
• GlaxoSmithKline
• Allergan
• Amgen
• Eli Lilly
• Teva Pharma
• Biohaven Pharma
• Johnson & Johnson
• Valeant Pharma
• AbbVie Inc
• Eli Lilly and Company
• Novartis International AG
• Novartis International AG
• Biohaven Pharmaceuticals
• Boehringer Ingelheim
• Zynerba Pharmaceuticals
• Teva Pharmaceutical
• Hoffmann-La Roche Ltd
• Amgen
• AstraZeneca

結論と推奨事項

Global Migraine Drugs Market size was valued at USD 3.89 Billion in 2022 and is poised to grow from USD 4.50 Billion in 2023 to USD 17.25 Billion by 2031, growing at a CAGR of 18.0% in the forecast period (2024-2031).

The migraine drug market is primarily focused on medications designed to alleviate or prevent migraine symptoms, categorized into acute and preventive medications. Acute treatments target immediate relief during migraine attacks, while preventive medications work to reduce the frequency and severity of these episodes. Key drivers of market growth include increasing awareness surrounding effective preventive options, advancements in diagnostic capabilities, and the introduction of innovative pharmaceuticals. However, challenges persist, such as the high cost of new therapies and the potential side effects that may lead to hesitancy among both healthcare providers and patients. Despite these obstacles, the migraine drug market is poised for significant expansion in the coming years, fueled by advancements in drug development, a shift toward personalized medicine, and promising opportunities within emerging markets. This combination of factors suggests a robust growth trajectory, as stakeholders seek to address unmet medical needs and improve patient outcomes in migraine management.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Migraine Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Migraine Drugs Market Segmental Analysis

Global Migraine Drugs Market is segmented by Treatment, Therapeutic Class, Route of Administration, Age Group, Availability and region. Based on Treatment, the market is segmented into Acute, Preventive. Based on Therapeutic Class, the market is segmented into CGRP monoclonal antibodies, CGRP small molecule antagonists, Acetylcholine inhibitors/ neurotoxins, Triptans, Ditans, Ergot alkaloids, NSAIDs, Others. Based on Route of Administration, the market is segmented into Oral, Injectable, Others. Based on Age Group, the market is segmented into Pediatric, Adult, Geriatric. Based on Availability, the market is segmented into Prescription Drugs, Over-the-Counter (OTC) Drugs. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Migraine Drugs Market

The Global Migraine Drugs market is significantly driven by the introduction of novel drug categories, such as CGRP gepants and inhibitors, which mark a substantial advancement in migraine management. These innovative treatments utilize targeted mechanisms, demonstrating superior efficacy in reducing both the severity and frequency of migraine attacks. As research into migraine pathophysiology continues to advance, the market is witnessing an influx of modernized therapies, including personalized treatment options informed by genetic and molecular insights. This dynamic landscape of innovative therapies not only enhances patient outcomes but also propels market growth by attracting investment and fostering a competitive environment among pharmaceutical companies.

Restraints in the Global Migraine Drugs Market

The global migraine drugs market faces significant restraints due to the variability in drug efficacy among patients, leading to inconsistent treatment outcomes and dissatisfaction. This discrepancy can prompt patients to seek alternative therapies, thereby limiting the uptake of conventional migraine medications. Furthermore, novel migraine treatments, while often effective, may present side effects that adversely affect patients' quality of life, potentially resulting in treatment discontinuation or the need for additional medications to manage these adverse effects. Such factors contribute to a hesitant patient base, ultimately hindering the overall growth and development of the migraine drug market.

Market Trends of the Global Migraine Drugs Market

The Global Migraine Drugs market is experiencing a significant trend towards the adoption of CGRP inhibitors, which have quickly emerged as preferred treatment options for migraine prophylaxis. Drugs like Aimovig, Emgality, and Ajovy have demonstrated remarkable efficacy in reducing both the frequency and severity of migraines, capturing the attention of healthcare providers and patients alike. Their convenient dosing options-either quarterly or monthly-add to their appeal, especially for chronic migraine sufferers seeking sustained relief. This shift towards targeted therapies indicates a broader movement within the pharmaceutical industry to prioritize personalized and effective migraine management solutions, thereby reshaping market dynamics and growth potential.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Driver & Opportunities
  • Restraints & Challenges
• Porters Analysis & Impact
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Technological Advancement
• Regulatory Landscape
• Patent Analysis
• Value Chain Analysis
• Case Study Analysis
• PESTEL Analysis
• Macro-Economic Indicators
• Trade Analysis
• Market Attractiveness Index
• Supply Chain Analysis
• Pricing Analysis

Global Migraine Drugs Market Size by Treatment & CAGR (2024-2031)

• Acute
• Preventive

Global Migraine Drugs Market Size by Therapeutic Class & CAGR (2024-2031)

• CGRP monoclonal antibodies
• CGRP small molecule antagonists
• Acetylcholine inhibitors/ neurotoxins
• Triptans
• Ditans
• Ergot alkaloids
• NSAIDs
• Others

Global Migraine Drugs Market Size by Route of Administration & CAGR (2024-2031)

• Oral
• Injectable
• Others

Global Migraine Drugs Market Size by Age Group & CAGR (2024-2031)

• Pediatric
• Adult
• Geriatric

Global Migraine Drugs Market Size by Availability & CAGR (2024-2031)

• Prescription Drugs
• Over-the-Counter (OTC) Drugs

Global Migraine Drugs Market Size & CAGR (2024-2031)

• North America, (Treatment, Therapeutic Class, Route of Administration, Age Group, Availability)
  • US
  • Canada
• Europe, (Treatment, Therapeutic Class, Route of Administration, Age Group, Availability)
  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe
• Asia-Pacific, (Treatment, Therapeutic Class, Route of Administration, Age Group, Availability)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America, (Treatment, Therapeutic Class, Route of Administration, Age Group, Availability)
  • Brazil
  • Rest of Latin America
• Middle East & Africa, (Treatment, Therapeutic Class, Route of Administration, Age Group, Availability)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Pfizer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biohaven Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Valeant Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biohaven Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zynerba Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendation